FDA Grants Nucynta New Indication
by Zangani • 10 November 2011 • Pain News
This is the second indication given to the oral μ-opioid agonist. Nucynta, a centrally acting synthetic agent, was previously approved for the treatment of acute pain. The ER formulation is taken twice daily when 24-hour pain relief is needed for extended periods.